Tulathromycin
(right click,save link as to download,it is a temp file,please download as soon as possible, you can also use CTRL+S to save the whole html page)
Basic Info
Common Name | Tulathromycin(F06197) |
2D Structure | |
FRCD ID | F06197 |
CAS Number | 217500-96-4 |
PubChem CID | 9832301 |
Formula | C41H79N3O12 |
IUPAC Name | (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-5-(propylaminomethyl)oxan-2-yl]oxy-3,5,8,10,12,14-hexamethyl-1-oxa-6-azacyclopentadecan-15-one |
InChI Key | GUARTUJKFNAVIK-QPTWMBCESA-N |
InChI | InChI=1S/C41H79N3O12/c1-15-17-42-22-41(50)28(8)53-31(20-39(41,10)51-14)55-33-25(5)35(56-37-32(45)29(44(12)13)18-24(4)52-37)38(9,48)19-23(3)21-43-27(7)34(46)40(11,49)30(16-2)54-36(47)26(33)6/h23-35,37,42-43,45-46,48-50H,15-22H2,1-14H3/t23-,24-,25+,26-,27-,28+,29+,30-,31+,32-,33+,34-,35-,37+,38-,39-,40-,41+/m1/s1 |
Canonical SMILES | CCCNCC1(C(OC(CC1(C)OC)OC2C(C(C(CC(CNC(C(C(C(OC(=O)C2C)CC)(C)O)O)C)C)(C)O)OC3C(C(CC(O3)C)N(C)C)O)C)C)O |
Isomeric SMILES | CCCNC[C@@]1([C@@H](O[C@H](C[C@@]1(C)OC)O[C@H]2[C@@H]([C@H]([C@](C[C@H](CN[C@@H]([C@H]([C@]([C@H](OC(=O)[C@@H]2C)CC)(C)O)O)C)C)(C)O)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)C)C)O |
Synonyms | UNII-897A3KN7AP DTXSID60274184 Tulathromycin A Tulathromycin 217500-96-4 Draxxin 897A3KN7AP Tulathrmycin A Tulathromycin A [USAN] SCHEMBL14672085 |
Classifies | Predicted: Veterinary Drug |
Update Date | Nov 13, 2018 17:07 |
Chemical Taxonomy
Kingdom | Organic compounds |
Superclass | Organic oxygen compounds |
Class | Organooxygen compounds |
Subclass | Carbohydrates and carbohydrate conjugates |
Intermediate Tree Nodes | Aminosaccharides |
Direct Parent | Aminoglycosides |
Alternative Parents |
|
Molecular Framework | Aliphatic heteromonocyclic compounds |
Substituents | Aminoglycoside core - Macrolide - Glycosyl compound - O-glycosyl compound - Monosaccharide - Oxane - Tertiary alcohol - 1,2-aminoalcohol - Amino acid or derivatives - Carboxylic acid ester - Lactone - Secondary alcohol - Tertiary amine - Tertiary aliphatic amine - Acetal - Organoheterocyclic compound - Secondary amine - Polyol - Azacycle - Carboxylic acid derivative - Dialkyl ether - Secondary aliphatic amine - Ether - Oxacycle - Monocarboxylic acid or derivatives - Carbonyl group - Organic nitrogen compound - Organopnictogen compound - Organic oxide - Alcohol - Hydrocarbon derivative - Amine - Organonitrogen compound - Aliphatic heteromonocyclic compound |
Description | This compound belongs to the class of organic compounds known as aminoglycosides. These are molecules or a portion of a molecule composed of amino-modified sugars. |
Properties
Property Name | Property Value |
---|---|
Molecular Weight | 806.092 |
Hydrogen Bond Donor Count | 7 |
Hydrogen Bond Acceptor Count | 15 |
Rotatable Bond Count | 11 |
Complexity | 1240 |
Monoisotopic Mass | 805.566 |
Exact Mass | 805.566 |
XLogP | 3.8 |
Formal Charge | 0 |
Heavy Atom Count | 56 |
Defined Atom Stereocenter Count | 18 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Isotope Atom Count | 0 |
Covalently-Bonded Unit Count | 1 |
ADMET
Model | Result | Probability |
---|---|---|
Absorption | ||
Blood-Brain Barrier | BBB- | 0.9918 |
Human Intestinal Absorption | HIA- | 0.7747 |
Caco-2 Permeability | Caco2- | 0.7511 |
P-glycoprotein Substrate | Substrate | 0.9265 |
P-glycoprotein Inhibitor | Inhibitor | 0.7321 |
Non-inhibitor | 0.8213 | |
Renal Organic Cation Transporter | Non-inhibitor | 0.8779 |
Distribution | ||
Subcellular localization | Lysosome | 0.7983 |
Metabolism | ||
CYP450 2C9 Substrate | Non-substrate | 0.8384 |
CYP450 2D6 Substrate | Non-substrate | 0.8682 |
CYP450 3A4 Substrate | Substrate | 0.6097 |
CYP450 1A2 Inhibitor | Non-inhibitor | 0.9537 |
CYP450 2C9 Inhibitor | Non-inhibitor | 0.8994 |
CYP450 2D6 Inhibitor | Non-inhibitor | 0.8934 |
CYP450 2C19 Inhibitor | Non-inhibitor | 0.9172 |
CYP450 3A4 Inhibitor | Non-inhibitor | 0.9486 |
CYP Inhibitory Promiscuity | Low CYP Inhibitory Promiscuity | 0.9858 |
Excretion | ||
Toxicity | ||
Human Ether-a-go-go-Related Gene Inhibition | Weak inhibitor | 0.9695 |
Non-inhibitor | 0.5891 | |
AMES Toxicity | Non AMES toxic | 0.9024 |
Carcinogens | Non-carcinogens | 0.9397 |
Fish Toxicity | High FHMT | 0.6586 |
Tetrahymena Pyriformis Toxicity | High TPT | 0.9494 |
Honey Bee Toxicity | Low HBT | 0.6566 |
Biodegradation | Not ready biodegradable | 0.9949 |
Acute Oral Toxicity | III | 0.6869 |
Carcinogenicity (Three-class) | Non-required | 0.5899 |
Model | Value | Unit |
---|---|---|
Absorption | ||
Aqueous solubility | -1.9958 | LogS |
Caco-2 Permeability | 0.0192 | LogPapp, cm/s |
Distribution | ||
Metabolism | ||
Excretion | ||
Toxicity | ||
Rat Acute Toxicity | 2.5888 | LD50, mol/kg |
Fish Toxicity | 1.8035 | pLC50, mg/L |
Tetrahymena Pyriformis Toxicity | 0.2842 | pIGC50, ug/L |
MRLs
Food | Product Code | Country | MRLs | Application Date | Notes |
---|---|---|---|---|---|
Cattle,Edible Offal | Japan | 3ppm | |||
Pig,Kidney | Japan | 9ppm | |||
Cattle,Kidney | Japan | 3ppm | |||
Pig,Fat | Japan | 0.3ppm | |||
Cattle,Fat | Japan | 0.2ppm | |||
Pig,Muscle | Japan | 2ppm | |||
Cattle,Muscle | Japan | 0.3ppm |
References
Title | Journal | Date | Pubmed ID |
---|---|---|---|
Injectable antimicrobials in commercial feedlot cattle and their effect on thenasopharyngeal microbiota and antimicrobial resistance. | Vet Microbiol | 2018 Feb | 29408026 |
Prevalence and antimicrobial susceptibility of Mannheimia haemolytica,Pasteurella multocida, and Histophilus somni isolated from the lower respiratory tract of healthy feedlot cattle and those diagnosed with bovine respiratorydisease. | Vet Microbiol | 2017 Sep | 28888626 |
Etiology of acute respiratory disease in fattening pigs in Finland. | Porcine Health Manag | 2017 Aug 23 | 28852568 |
Whole Genome Sequence Analysis of Pig Respiratory Bacterial Pathogens withElevated Minimum Inhibitory Concentrations for Macrolides. | Microb Drug Resist | 2016 Oct | 26981707 |
Estimation of tulathromycin depletion in plasma and milk after subcutaneousinjection in lactating goats using a nonlinear mixed-effects pharmacokineticmodeling approach. | BMC Vet Res | 2016 Nov 18 | 27863483 |
Antimicrobial susceptibility of Mycoplasma bovis isolates from veal calves anddairy cattle in the Netherlands. | Vet Microbiol | 2016 Jun 30 | 27259820 |
Pharmacokinetics and lung and muscle concentrations of tulathromycin followingsubcutaneous administration in white-tailed deer (Odocoileus virginianus). | J Vet Pharmacol Ther | 2016 Jun | 26669905 |
Antimicrobial resistance genes in Actinobacillus pleuropneumoniae, Haemophilusparasuis and Pasteurella multocida isolated from Australian pigs. | Aust Vet J | 2016 Jul | 27349882 |
Development of Analytical Method and Monitoring of Veterinary Drug Residues inKorean Animal Products. | Korean J Food Sci Anim Resour | 2016 | 27433102 |
Pharmacokinetics of tulathromycin after subcutaneous injection in North American bison (Bison bison). | J Vet Pharmacol Ther | 2015 Oct | 25772094 |
Development and validation of determinative and confirmatory LC-MS/MSmethodologies for total florfenicol and tulathromycin residues in bovine, equine and porcine kidney, liver and muscle tissues. | J Chromatogr B Analyt Technol Biomed Life Sci | 2015 Mar 1 | 25612770 |
Clinical evidence for individual animal therapy for papillomatous digitaldermatitis (hairy heel wart) and infectious bovine pododermatitis (foot rot). | Vet Clin North Am Food Anim Pract | 2015 Mar | 25705026 |
Antimicrobial susceptibility of Histophilus somni isolated from clinicallyaffected cattle in Australia. | Vet J | 2015 Feb | 25592262 |
Pharmacokinetics of tulathromycin in edible tissues of healthy and experimentallyinfected pigs with Actinobacillus pleuropneumoniae. | Food Addit Contam Part A Chem Anal Control Expo Risk Assess | 2015 | 26247868 |
Use of a proposed antimicrobial susceptibility testing method for Haemophilusparasuis. | Vet Microbiol | 2014 Aug 27 | 24984947 |
Pharmacokinetics of tulathromycin in plasma and milk samples after a singlesubcutaneous injection in lactating goats (Capra hircus). | J Vet Pharmacol Ther | 2014 Apr | 23889045 |
Impact of health management, health treatments, and zilpaterol hydrochloridesupplementation on carcass quality, color, and palatability traits in heifers. | J Anim Sci | 2013 Jul | 23658348 |
Estimating tulathromycin withdrawal time in pigs using a physiologically basedpharmacokinetics model. | Food Addit Contam Part A Chem Anal Control Expo Risk Assess | 2013 | 23767965 |
Pharmacokinetics and tissue elimination of tulathromycin following subcutaneousadministration in meat goats. | Am J Vet Res | 2012 Oct | 23013191 |
Pharmacokinetics of tulathromycin and its metabolite in swine administered withan intravenous bolus injection and a single gavage. | J Vet Pharmacol Ther | 2012 Jun | 21749408 |